Skip to main content

Table 1 Summary of clinicopathological features and follow up of patients with pancreatic cancer

From: Epigenetic silencing of AATK in acinar to ductal metaplasia in murine model of pancreatic cancer

Characteristics

Number (%)

AATK expression

P

Low

High

Age

< 65

41 (49.4)

32 (78.0)

9 (22.0)

0.055

> 65

42 (50.6)

39 (92.9)

3 (7.1)

 

Sex

Male

28 (33.7)

23 (82.1)

5 (17.9)

0.530

Female

55 (66.3)

48 (87.3)

7 (12.7)

 

Tumor location

Head

52 (62.7)

43 (82.7)

9 (17.3)

0.142

Neck

6 (7.2)

6 (100.0)

0 (0.0)

 

Body

4 (4.8)

2 (50.0)

2 (50.0)

 

Tail

6 (7.2)

6 (100.0)

0 (0.0)

 

Uncinate

10 (12.0)

10 (100.0)

0 (0.0)

 

Others

5 (6.0)

4 (80.0)

1 (20.0)

 

Tumor size, cm

≤ 3

47 (56.6)

40 (85.1)

7 (14.9)

0.897

> 3

36 (43.4)

31 (86.1)

5 (13.9)

 

Tumor grade

Poorly differentiated

17 (20.5)

16 (94.1)

1 (5.9)

0.466

Moderately differentiated

46 (55.4)

39 (84.8)

7 (15.2)

 

Well differentiated

20 (24.1)

16 (80.0)

4 (20.0)

 

Stage

I

9 (10.8)

7 (77.8)

2 (22.2)

0.733

II

69 (83.1)

59 (85.5)

10 (14.5)

 

III

4 (4.8)

4 (5.6)

0 (0.0)

 

IV

1 (1.2)

1 (100.0)

0 (0.0)

 

Recurrence status

Absent

22 (26.5)

18 (81.8)

4 (18.2)

0.562

Present

61 (73.5)

53 (86.9)

8 (13.1)

 

Metastatic status

Absent

39 (47.0)

32 (82.1)

7 (17.9)

0.395

Present

44 (53.0)

39 (88.6)

5 (11.4)

 

CA199

< 37U/ml

14 (16.9)

12 (85.7)

2 (14.3)

0.987

> 37U/ml

63 (75.9)

54 (85.7)

9 (14.3)